Lv3
202 积分 2021-07-21 加入
Development of PROTAC Degrader Drugs for Cancer
18天前
已完结
Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer
21天前
已完结
Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC
25天前
已完结
Discovery of a Novel Orally Bioavailable FLT3-PROTAC Degrader for Efficient Treatment of Acute Myeloid Leukemia and Overcoming Resistance of FLT3 Inhibitors
25天前
已完结
Development of an Orally Bioavailable LCK PROTAC Degrader as a Potential Therapeutic Approach to T-Cell Acute Lymphoblastic Leukemia
25天前
已完结
Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer
25天前
已完结
Selective and Orally Bioavailable c-Met PROTACs for the Treatment of c-Met-Addicted Cancer
25天前
已完结
Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition
25天前
已完结
Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader
25天前
已完结
Correction to “Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer”
25天前
已完结
皖公网安备34019202002308
